The Board of Directors of Biovica International AB, corporate identity number 556774-6150, hereby convenes the Annual General Meeting on 27 August 2020 at 16:00 in the company’s premises at Dag Hammarskjölds väg 54B, Uppsala Science Park, Uppsala.
Biovica’s annual report for the fiscal year 2019/2020 is published on our website https://biovica.com/investor-relations/financials/ Contact Anders Rylander, CEOPhone: +46-18-444 48 35E-mail: email@example.com Cecilia Driving, EVP CFO/HR/IRPhone +46-73-125 92 47E-mail: firstname.lastname@example.org Biovica – Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica’s assay DiviTum® measure cell proliferation […]
Preparations for the launch of DiviTum® have started
Uppsala, Sweden, May 11, 2020. Biovica, active in cancer diagnostics, hosts today its virtual capital market day at 14.00-16.00. The purpose is to provide an update on Biovica’s market launch strategy and goals. Biovica is also providing a market share target three years after launch of DiviTum®.
Period: May-January 2019/2020
“The results from two additional studies with DiviTum® will be presented at San Antonio Breast Cancer Symposium, the world’s largest scientific conference on breast cancer”. – Anders Rylander, CEO of Biovica
SEK thousands Q1 19/20 Q1 18/19 May-April 18/19 Net sales 367 914 3,005 Operating profit (loss) -6,097 -3,956 -21,718 Profit (loss) for the period -6,068 -4,028 -21,556 Earnings per share, after dilution -0.33 -0.23 -1.18 Significant events during the first quarter Targeted new share issue for SEK 60 million to European and Swedish institutional investors […]
Biovica’s annual report for the fiscal year 2018/2019 is published on our website https://www.biovica.com/investor-relations/financials/
FDA-process and commercialization on track. New study results confirm the potential. Year-End Report (May-January 2018/2019)
SEK thousands Q4 18/19 Q4 17/18 May-April 18/19 May-April 17/18 Net sales 1,715 1,433 3,005 2,723 Operating profit (loss) -8,569 -4,132 -21,718 -17,956 Loss for the period -8,631 -4,176 -21,556 -18,010 Earnings per share, after dilution -0.47 -0.24 -1.18 -1.01
The extra general meeting (“EGM”) of Biovica International AB (publ) (“Biovica” or the “Company”) was held today on 2 May 2019 and the following resolutions were passed by the meeting. Resolution regarding approval of the board of directors’ resolution to issue new class B shares with deviation from the shareholders’ preferential rights